Den europeiske union - norsk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease virus, serotype 1, strain rn1250; live recombinant turkey herpesvirus, expressing the vp2 protein of infectious bursal disease virus, strain vhvt013-69 - immunologicals for aves, domestic fowl, avian herpes virus (marek's disease) + avian infectious bursal disease virus (gumboro disease) + newcastle disease virus/paramyxovirus - kylling - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus), and to prevent mortality, clinical signs and lesions caused by infectious bursal disease (ibd) virus.

Den europeiske union - norsk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease (md) virus, serotype 1, strain rn1250 - immunologicals for aves - kylling - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus).

Den europeiske union - norsk - EMA (European Medicines Agency)

ceva-phylaxia veterinary biologicals co. ltd - turkey herpes virus, strain rhvt/nd/ibd, expressing the fusion protein of newcastle disease virus and the vp2 protein of infectious bursal disease virus, live recombinant - immunologicals for aves - embryonated chicken eggs; chicken - for the active immunisation of one-day-old chicks or 18-day-old chicken embryonated eggs to reduce mortality, clinical signs and lesions caused by newcastle disease virus (ndv) and to reduce virus shedding; to reduce mortality, clinical signs and bursa lesions caused by very virulent infectious bursal disease virus (ibdv); to reduce mortality, clinical signs and lesions caused by classical marek’s disease virus (mdv).

Den europeiske union - norsk - EMA (European Medicines Agency)

intervet international b.v. - cell-associated live recombinant turkey herpesvirus (strain hvt/ndv/ilt) expressing the fusion protein of newcastle disease virus and the glycoproteins gd and gi of infectious laryngotracheitis virus - immunologicals for aves - embryonated chicken eggs; chicken - for active immunisation of one-day-old chicks or embryonated chicken eggs:to reduce mortality and clinical signs caused by newcastle disease (nd) virus,to reduce mortality, clinical signs and lesions caused by avian infectious laryngotracheitis (ilt) virus and marek’s disease (md) virus.

Den europeiske union - norsk - EMA (European Medicines Agency)

intervet international b.v. - celle-forbundet live rekombinant tyrkia herpes-virus (belastning hvp360), uttrykker fusion protein av nd-virus og vp2 protein av ibd virus - avian herpes virus (marek ' s sykdom) + avian smittsomme bursal disease virus (gumboro sykdom) + newcastle disease virus/paramyxovirus - chicken; embryonated chicken eggs - for active immunisation of one-day-old chicks or 18-19-day-old embryonated chicken eggs:to reduce mortality and clinical signs caused by newcastle disease (nd) virus,to prevent mortality and to reduce clinical signs and lesions caused by infectious bursal disease (ibd) virus,to reduce mortality, clinical signs and lesions caused by marek’s disease (md) virus.

Den europeiske union - norsk - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - kylling - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

Den europeiske union - norsk - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - celleassosiert levende rekombinant kalkunherpesvirus (rhvt / nd) som uttrykker fusjonsproteinet av newcastle disease-virusen d-26 lentogen stamme - immunologicals for aves, live viral vaksiner - chicken; embryonated eggs - for aktive vaksinering av 18 dagers gammel embryonated kylling egg eller en-dag-gamle damer for å redusere dødelighet og kliniske tegn forårsaket av newcastle disease virus, og for å redusere dødelighet, kliniske tegn og lesjoner forårsaket av marek ' s disease virus med en phenotype "ondartet".

Den europeiske union - norsk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - rekombinant tyrkia herpes-virus, belastning vhvt013-69, live - immunologicals for aves, innenlandske fugler, immunologicals - embryonated eggs; chicken - for aktive vaksinering av kyllinger:for Å forhindre dødelighet og for å redusere kliniske tegn og lesjoner av smittsom sykdom bursal. for å redusere dødelighet, kliniske tegn og lesjoner av marek ' s sykdom.

Den europeiske union - norsk - EMA (European Medicines Agency)

laboratorios hipra s.a - levende ge- tk-dobbeltgen-slettet bovint herpesvirus type 1, stamme ceddel: 106,3-107,3 ​​ccid50 - immunologicals - kveg - for aktiv immunisering av storfe fra tre måneders alder mot bovin herpesvirus type 1 (bohv-1) for å redusere de kliniske tegnene på infeksiøs bovin rhinotracheitt (ibr) og feltvirusutskillelse. immunitetens begynnelse: 21 dager etter at grunnvaksinasjonsordningen er fullført. immunitetens varighet: 6 måneder etter at grunnvaksinasjonsordningen er fullført.

Den europeiske union - norsk - EMA (European Medicines Agency)

zoetis belgium sa - live recombinant e2 gene-deleted bovine viral diarrhoea virus containing classical swine fever virus e2 gene (cp7_e2alf) - live viral vaccines, immunologicals for suidae - griser - for aktiv immunisering av griser fra 7 ukers alder og framover for å forhindre dødelighet og redusere infeksjon og sykdom forårsaket av klassisk svinepestvirus (csfv). onset of immunity: 14 days after vaccinationduration of immunity: at least 6 months after vaccinationfor active immunisation of breeding females to reduce transplacental infection caused by csfv. onset of immunity: 21 days after vaccinationduration of immunity has not been demonstrated.